Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes
- Resource Type
- Article
- Source
- In
Journal of Controlled Release January 2023 353:254-269 - Subject
- Language
- ISSN
- 0168-3659